Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical resiquimod gel 0.06% for nodular basal cell carcinoma
2012-002845-40Phase 2Terminated
- Sponsor
- Galderma
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of resiquimod in basal cell carcinoma (BCC), sponsored by Galderma. Started Sep 2012; status: terminated.
02
Drugs
resiquimod
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2012-002845-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002845-40.